Night Vision After Trifocal Lens Surgery: What Patients Experience

This page is for patients considering or recovering from trifocal IOL implantation who want to understand what night vision changes to expect, why halos occur, and when they resolve.

Halos Are the Optical Signature of Multifocality

Patient satisfaction at twelve months exceeds 95% in Mr Hove’s RLE series, including patients who experienced prominent halos in the first weeks. Trifocal intraocular lenses create three focal points by splitting incoming light across a diffractive ring structure. This splitting is highly efficient, published energy distribution data shows approximately 50% of light directed to distance, 20% to intermediate, and 20% to near, with approximately 10% scatter. It is this scatter, combined with the diffractive ring profile, that produces the halo signature seen around point light sources, particularly in dim light conditions where the pupil dilates and more of the diffractive structure is engaged.

Halos with trifocal IOLs are not a defect. They are the optical consequence of the multifocal design, the trade that delivers spectacle independence at all distances. This is often not explained clearly before surgery, which is why patients who experience halos in the first weeks are disproportionately distressed. The information, delivered before surgery, converts a surprise into an expectation.

The Neuroadaptation Timeline

Use the following to locate your current timepoint and understand whether your halo experience is on track for normal neuroadaptation:

• Week 1-2: 70-80% of patients report prominent halos. Expected, not alarming.
• Week 4-6: 30-40% of patients. Reducing, neuroadaptation progressing.
• 3 months: 10-15% of patients. Mild residual, most not functionally limiting.
• 6 months: under 10% of patients. Neuroadaptation largely complete.
• 12 months: under 5% of patients. Settled state, persistent halos rare.

When Halos Are a Red Flag

Halos that are present at twelve months and have not progressively reduced since the first weeks are not the expected neuroadaptation pattern. If halos are worsening rather than reducing, or if they are accompanied by reduced visual acuity, assessment is warranted. Posterior capsule opacification (PCO), which develops in 20-30% of patients within two to five years, can produce or amplify halos. YAG capsulotomy resolves this within days.

Patient Selection and Halos

Not every patient is an appropriate trifocal candidate. Patients with pre-existing ocular pathology, particularly macular degeneration, diabetic maculopathy, or significant glaucoma, may have reduced capacity to neuroadapt and are more likely to find trifocal halos functionally limiting. Patients with occupational requirements for very precise night vision, some professional drivers or pilots, may find the trifocal optical profile incompatible with their work. Monofocal IOL is the appropriate choice for this group, accepting spectacle dependence for near in exchange for optimal optical purity at distance.

Clinical Perspective

At Blue Fin Vision® clinic, Mr Mfazo Hove incorporates specific trifocal halo counselling into every RLE consultation. Patients are shown simulated halo images representing the early post-operative appearance, the expected appearance at three months, and the typical twelve-month settled state. This visual reference converts abstract description into concrete expectation. In our 2024-2025 RLE series, patient satisfaction at twelve months was above 95%, a figure that reflects accurate pre-operative counselling as much as surgical technique.

Clinical Takeaway

Halos after trifocal IOL implantation are expected and are the optical consequence of the diffractive design. Prevalence reduces from 70-80% at week one to under 5% at twelve months as neuroadaptation occurs. At Blue Fin Vision®, Mr Mfazo Hove provides specific halo counselling with visual simulation at every trifocal consultation. Halos that worsen rather than improve warrant assessment for PCO. If your halos are worsening after the first six weeks, book a review, do not assume this is normal neuroadaptation.

References

1. Kohnen T, Titke C, Bohm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal: 3-year follow-up. Am J Ophthalmol. 2016;161:71-7.
2. Gundersen KG, Potvin R. Trifocal intraocular lenses: a comparison of the visual performance and quality of vision reported in two groups of patients implanted with the same lens design. Clin Ophthalmol. 2017;11:1081-7.
3. Cochener B, Boutillier G, Lamard M, Auber C. A comparative evaluation of a new generation of diffractive trifocal and extended depth of focus intraocular lenses. J Refract Surg. 2018;34(8):507-14.
4. Sudhir RR, Dey A, Bhatt S, Bahulayan A. AcrySof IQ PanOptix intraocular lens versus extended depth of focus intraocular lens and trifocal intraocular lens: a clinical overview. Asia Pac J Ophthalmol. 2019;8(4):335-49.
5. Conrad-Hengerer I, Al Juburi M, Tandogan T, Hengerer FH, Kohnen T. Contrast sensitivity and visual acuity in patients implanted with a diffractive trifocal intraocular lens. J Cataract Refract Surg. 2013;39(12):1783-92.